
Opinion|Videos|June 28, 2024
CLL Treatment Landscape: Overview of BTK Inhibitors
A panel of experts provide an overview of BTK inhibitors for the treatment of patients with chronic lymphocytic leukemia.
Advertisement
Episodes in this series

Video content above is prompted by the following question(s):
- Provide an overview of the current landscape of treatment-naïve CLL treatment options. Where do the BTK inhibitors fit into this landscape?
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on AJMC
1
Mirvetuximab Soravtansine Demonstrates Promising Efficacy, Safety in Platinum-Resistant Recurrent Ovarian Cancer
2
How Artificial Intelligence Is Transforming Leukemia Detection and Diagnosis
3
Zanubrutinib Shows Similar Efficacy but Better Safety Than VEN–I in Frontline CLL
4
FDA Approves Sibeprenlimab for Immunoglobulin A Nephropathy
5













































